Abbreviations
- AML:
-
Acute myeloid leukaemia
- mDC:
-
Myeloid dendritic cell
- MICA/B:
-
MHC class I polypeptide-related sequence A/B
- Nrf2:
-
Nuclear factor (erythroid-derived 2)-like 2
- pDC:
-
Plasmacytoid dendritic cell
- Th1:
-
T helper cell type 1
- Treg:
-
Regulatory T cell
Acknowledgments
We thank the following companies and organisations for sponsoring the meeting: CTL Europe, CureVac, Immatics, Springer Nature, European Federation of Immunological Societies (EFIS), Autoimmun Diagnostika (AID), Becton Dickinson (BD), CellGenix, JPT Peptide Technologies, Pantec Biosolutions, Faculty of 1000 and the European Association for Cancer Research (EACR). We are especially grateful to Kathryn Wass and Laura Strachan of the EACR for their outstanding work in organising the meeting, without which it would not have been the resounding success that it was. We also gratefully acknowledge Alexander Martens, Lisa Speigl, Kilian Wistuba-Hamprecht and Nicole Janssen for their assistance in the preparation of this report.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that they have no conflict of interest. Graham Pawelec is chair of the PIVAC scientific organising committee.
Additional information
This meeting report is a summary of presentations from the Fifteenth International Conference on Progress in Vaccination against Cancer, PIVAC 15, published together with a series of Focussed Research Reviews based on lectures given at the conference.
Rights and permissions
About this article
Cite this article
Shipp, C., Pawelec, G. The fifteenth International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6–8 October 2015, Tübingen, Germany: looking back on 15 years of progress. Cancer Immunol Immunother 66, 273–279 (2017). https://doi.org/10.1007/s00262-016-1888-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-016-1888-4